G1 touts PhII can­cer da­ta, but shares tank on place­bo re­sults; Mer­ck bags an­oth­er ap­proved in­di­ca­tion for Keytru­da

→ G1 Ther­a­peu­tics $GTHX tried their lev­el best to tout the re­sults of their Phase II study of tri­laci­clib in com­bi­na­tion with topote­can for small cell lung can­cer, demon­strat­ing myelo­p­reser­va­tion ben­e­fits. In­vestors, though, couldn’t get past the fact that the ORR rate was high­er in the place­bo group com­pared to their drug. The stock tanked, drop­ping by more than 30% on Thurs­day morn­ing.

→ Pfiz­er and their part­ners at Astel­las say that a Phase III study of Xtan­di plus an­dro­gen de­pri­va­tion ther­a­py — ADT — in hor­mone-sen­si­tive prostate can­cer met the pri­ma­ry end­point in ra­di­ograph­ic progress-free sur­vival when com­pared to ADT alone. “While XTAN­DI is cur­rent­ly ap­proved for both metasta­t­ic and non-metasta­t­ic CR­PC, there still re­mains a need for more treat­ment op­tions for men with metasta­t­ic hor­mone-sen­si­tive prostate can­cer,” said Mace Rothen­berg, who heads up Pfiz­er’s on­col­o­gy R&D group. “With these top-line re­sults, we be­lieve XTAN­DI has the po­ten­tial to help men whose dis­ease has pro­gressed out­side the prostate gland, but still re­sponds to treat­ment to low­er testos­terone.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.